The presence of anti-PS antibodies is also considered a risk factor for thrombosis and associated with disease severity in systemic lupus erythematosus (SLE), APS, COVID-19, and cardiovascular disease patients (89–95). Here, PRB2 is linked to cardiovascular disorder.